A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression
Figure 1
Body weight is not affected by treatment with LM11A-31 in male APPL/S mice.
Body weights of (A) 9–11 month old male APPL/S mice treated with LM11A-31 (50 mg/kg) for 3 months (WT Veh, n = 9 mice; WT-31, n = 10; APP Veh, n = 10; APP-31, n = 9) and (B) 13–14 month old male APPL/S mice treated with LM11A-31 (50 mg/kg) for 1 month (WT Veh, n = 5 mice; APP Veh, n = 4; APP-31, n = 5). APP mice weighed significantly less than WT mice in both of the age groups examined. LM11A-31 did not affect body weight at either age or genotype. Statistical significance was determined using repeated measures ANOVA with Dunnett's post-hoc test.